Gen-Probe HIV test
This article was originally published in The Gray Sheet
Executive SummaryFirm announces FDA approval of the Aptima HIV-1 RNA qualitative genetic test Oct. 5. Gen-Probe plans to launch the test in November with its Aptima HCV RNA qualitative assay for the hepatitis C virus. The tests "fill a small-yet-important medical niche" in detecting the presence of viral genetic material, said Steve Kondor, the firm's VP-sales & marketing. The HIV test is the first approved nucleic acid test indicated to aid in the diagnosis of HIV-1 infection and to confirm infections in certain patients, according to Gen-Probe. Bayer has sold the HCV test as a co-exclusive marketer under the Versant brand since its approval in 2002. Gen-Probe has not marketed the HCV test before...
You may also be interested in...
As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.
Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.